Larka’s Post

Join your peers for this must-attend #webinar reviewing different types of linkers and payloads used in antibody-drug conjugates, as well as key methodologies involved in developing robust bioassays for #ADCs. Register today to gain access to the live event and on-demand recording. #medicinalchemistry #biotechnology #ADC #cellbasedassay #drugdiscovery #biology #chemistry #CDMO

Celebrating CARBOGEN AMCIS colleague Luca Mannocci! It's great to see our scientists' talents highlighted in industry trade publications! Learn more about our ADC and bioconjugation expertise by starting the conversation today! How can we help bring your science to life? #ADCs #bioconjugation #CDMO #bringingyoursciencetolife

How has Propanc Biopharma optimized the formulation of their lead asset? We invite you to listen as Dr. Ralf Brandt, Propanc’s Scientific Advisory Board Member & Co-Inventor describes the process for taking the formulation from that compassionate use study that observed such positive results, and how the team further improved that same formulation with the goal of seeing even more efficacious results!   #propanc #ppcb #biopharma #cancer #oncology

We have come far to decrease cancer mainly in prostate and breast and increased FDA drug approvals as summarized by Dr. Rathmell Director National Cancer Institute. However much more is needed to help our patients! #ASCO2024 #cancer #Agilent #precisionmedicine

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

Umoja Biopharma is at the forefront of cancer immunotherapies. This year, they received IND clearance for the Phase I trial of UB-VV111, an in vivo CAR T-cell therapy to treat blood cancers. 👏 See how they’ve used Benchling to accelerate their R&D by: ✔️ Creating a standardized data structure ✔️ Establishing a centralized system of record ✔️ Improving collaboration between 11 R&D teams, across 3 sites https://lnkd.in/eV5DGmPs #BuiltOnBenchling

One of the most anticipated topics at #ESMO24 was immunotherapy breakthroughs, according to Worldwide's poll. Interested in learning more about how to incorporate this innovative treatment into trial design? Discover critical insights into immunotherapy for your oncology program in our white paper: https://ow.ly/fzkq50TCvKP

Radiopharmaceuticals are emerging as a powerful avenue for treating cancer. In this interview, Dr Jack Hoppin and Dr John Babich, Ratio Therapeutics, talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit. "You have the opportunity to not only reduce tumor burden and control tumor growth, but also stimulate inflammation locally on every site that the radioactivity lands on." Read the full interview here: https://lnkd.in/e7iG9WHX #IO360Summit #immunooncology #radiopharmaceuticals

As our understanding of the role of complement in cancer expands, we can begin to see new connections and treatment opportunities For example, a new review highlights the context dependent role of complement in cancer and the potential for stratifying patients based on complement status to appropriately target complement alone or in combination with other anti-cancer therapies to enhance efficacy. You can read the review here: https://lnkd.in/ecbp3_cT What might help examine these interactions more closely? Accurate complement activation testing during drug development to both maximize benefits and limit risks. Find out more about Kypha’s expertise at https://lnkd.in/eHgaBzYJ #complement #bispecifics #immunotherapies #diagnostics #complementdiagnostics #immunemonitoring #cancertherapeutics

Our recent CASES report provides strategic insights into advanced cervical cancer treatment practices across the Midwest. The report covers frontline and second-line therapy trends, biomarker-driven approaches, and expert perspectives from top oncologists. Peek inside this report! https://lnkd.in/ejzGrKmm #OncologyInsights #Pharma #CancerCare